Maktabi Maryam, Chamani Maryam, Asemi Zatollah
Department of Gynecology and Obstetrics, Endocrinology and Metabolism Research Center, School of Medicine, Arak University of Medical Sciences, Arak, I. R. Iran.
Department of Gynecology and Obstetrics, School of Medicine, Iran University of Medical Sciences, Tehran, I. R. Iran.
Horm Metab Res. 2017 Jul;49(7):493-498. doi: 10.1055/s-0043-107242. Epub 2017 Jul 5.
Data on the effects of vitamin D supplementation on metabolic status of patients with polycystic ovary syndrome (PCOS) are scarce. The current study was conducted to evaluate the effects of vitamin D supplementation on metabolic status of patients with PCOS. This randomized double-blind, placebo-controlled trial was performed on 70 vitamin D-deficient (serum concentrations<20 ng/ml) women with phenotype B-PCOS according to the Rotterdam criteria aged 18-40 years old. Participants were randomly allocated into 2 groups to take either 50 000 IU vitamin D (n=35) or placebo (n=35) every 2 weeks for 12 weeks. Metabolic, endocrine, inflammation, and oxidative stress biomarkers were quantified at the beginning of the study and after 12-week intervention. After the 12-week intervention, compared to the placebo, vitamin D supplementation significantly decreased fasting plasma glucose (FPG) (-3.1±7.3 vs. +0.5±6.3 mg/dl, p=0.02), insulin (-1.4±3.6 vs. +2.6±7.0 μIU/ml, p=0.004), homeostasis model of assessment-estimated insulin resistance (-0.3±0.8 vs. +0.6±1.6, p=0.003), homeostasis model of assessment-estimated B cell function (-4.9±13.4 vs. +9.9±26.9, p=0.005), and increased quantitative insulin sensitivity check index (+0.01±0.01 vs. -0.02±0.05, p=0.007). Supplementation with vitamin D also led to significant reductions in serum high-sensitivity C-reactive protein (hs-CRP) (-0.7±1.4 vs. +0.5±2.1 μg/mL, p=0.009) and plasma malondialdehyde (MDA) levels (-0.1±0.5 vs. +0.9±2.1 μmol/l, p=0.01) compared to the placebo. Overall, vitamin D supplementation for 12 weeks in vitamin D-deficient women with phenotype B-PCOS had beneficial effects on glucose homeostasis parameters, hs-CRP, and MDA.
关于补充维生素D对多囊卵巢综合征（PCOS）患者代谢状况影响的数据很少。本研究旨在评估补充维生素D对PCOS患者代谢状况的影响。本随机双盲、安慰剂对照试验针对70名年龄在18至40岁之间、根据鹿特丹标准诊断为B型PCOS且维生素D缺乏（血清浓度<20 ng/ml）的女性进行。参与者被随机分为两组，每2周分别服用50000 IU维生素D（n = 35）或安慰剂（n = 35），持续12周。在研究开始时和12周干预后对代谢、内分泌、炎症和氧化应激生物标志物进行定量。12周干预后，与安慰剂组相比，补充维生素D显著降低了空腹血糖（FPG）（-3.1±7.3 vs. +0.5±6.3 mg/dl，p = 0.02）、胰岛素（-1.4±3.6 vs. +2.6±7.0 μIU/ml，p = 0.004）、稳态模型评估估计的胰岛素抵抗（-0.3±0.8 vs. +0.6±1.6，p = 0.003）、稳态模型评估估计的B细胞功能（-4.9±13.4 vs. +9.9±26.9，p = 0.005），并提高了定量胰岛素敏感性检查指数（+0.01±0.01 vs. -0.02±0.05，p = 0.007）。与安慰剂相比，补充维生素D还导致血清高敏C反应蛋白（hs-CRP）（-0.7±1.4 vs. +0.5±2.1 μg/mL，p = 0.009）和血浆丙二醛（MDA）水平（-0.1±0.5 vs. +0.9±2.1 μmol/l，p = 0.01）显著降低。总体而言，对维生素D缺乏的B型PCOS女性补充维生素D 12周对血糖稳态参数、hs-CRP和MDA有有益影响。
